Obinutuzumab in Chinese Real-world Patients With iNHL
NCT05968001 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2023-08-01
Summary
This study aims to assess the clinical efficacy and safety of obinutuzumab in Chinese patients with indolent non-Hodgkin B-cell Lymphoma (predominantly Follicular lymphoma and Marginal zone lymphoma) in a real-world setting.
Conditions
- Lymphomas Non-Hodgkin's B-Cell
Interventions
- DRUG
-
obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
Sponsors & Collaborators
-
Affiliated Hospital of Nantong University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-20
- Primary Completion
- 2024-12-30
- Completion
- 2026-07-20
- FDA Drug
- Yes
Countries
- China
Study Locations
More Related Trials
-
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
NCT03299738 ·Status: UNKNOWN ·Phase: PHASE1
-
Real World Study of Linperlisib for Lymphoma Treatment
NCT05863871 ·Status: NOT_YET_RECRUITING
-
Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
NCT06592170 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
NCT06513234 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
NCT05954910 ·Status: ACTIVE_NOT_RECRUITING
-
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
NCT06594432 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
NCT03332017 ·Status: COMPLETED ·Phase: PHASE2
-
A Retrospective Study on Extranodal DLBCL
NCT06549361 ·Status: COMPLETED
-
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT06693973 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma
NCT04899570 ·Status: UNKNOWN ·Phase: PHASE2
-
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma
NCT06415708 ·Status: RECRUITING ·Phase: PHASE2
-
A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT04129710 ·Status: RECRUITING ·Phase: PHASE2
-
Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
NCT06961500 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
NCT05846763 ·Status: RECRUITING
-
B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma
NCT03332121 ·Status: COMPLETED ·Phase: PHASE1
-
Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years
NCT05429918 ·Status: UNKNOWN
-
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
NCT06793189 ·Status: RECRUITING ·Phase: PHASE2
-
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
NCT05169658 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
NCT05039658 ·Status: UNKNOWN ·Phase: PHASE1
-
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
NCT06656234 ·Status: NOT_YET_RECRUITING
-
Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma
NCT05486013 ·Status: RECRUITING
-
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05797948 ·Status: UNKNOWN ·Phase: NA
-
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
NCT06454968 ·Status: RECRUITING ·Phase: PHASE2
-
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission
NCT05596097 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04657302 ·Status: COMPLETED ·Phase: PHASE1